The serine protease, prostate-specific antigen (PSA), its protein substrates, semenogelin (Sg) I and 11, and protein C inhibitor (PCI) have been described as components of human seminal plasma. PCI was found to inhibit the PSA-catalyzed degradation of insoluble coagula Sg If11 by forming a PSA-PCI complex. Digestion of seminal coagula with PSA released PCI and PSA-PCI complex from the coagula into a soluble phase, suggesting the presence of active PCI binding to the coagula. To investigate the molecular interaction of Sg with PSA and PCI, we purified Sg I1 from seminal coagula as a soluble form and found that Sg I1 is glycosylated with heterogeneous carbohydrate moieties. Sg I1 bound to the solidphase complex of diisopropylfluorophosphate (iPr,FP) and PSA with an apparent dissociation constant (Kd) of 41 nM and to PCI with a Kd of 28 nM. The binding of Sg TI to iPr,P-PSA was not affected by PCI and that of Sg I1 to PCI was not affected by iPr,P-PSA, suggesting that Sg I1 forms a ternary complex with PSA and PCI. The bindings of Sg I1 to both iPr,P-PSA and PCI were influenced by pH, ionic strength. heparin, dextran sulfate, and divalent cations, particularly by Znz+. Treatment of Sg I1 with heparinase, heparitinase, N-glycanase, or with 0-glycanase following sialidase did not affect the binding of Sg I1 to iPr,P-PSA and PCI. These findings suggested that PCI bound to Sg in seminal vesicles regulates the PSA-catalyzed degradation of Sg in seminal plasma, and that the binding of PCI and PSA to Sg is modulated by several factors such as pH, ionic strength, divalent cations, and heparin-like substances in seminal plasma.Keywords: prostate-specific antigen ; protein C inhibitor; semenogelin; seminal plasma; prostate-specificantigen -protein-C-inhibitor complex.Protein C inhibitor (PCI), a member of the plasma serine protease inhibitor (serpin) family, is an inhibitor of activated protein C (APC), the main proteolytic enzyme of the protein C anticoagulant pathway [I -31. During the PCI-mediated inhibition of APC, PCI forms an acyl-bond complex with APC [2]. This complex formation is enhanced by heparin and negatively charged dextran sulfate. Patients with venous thrombosis and disseminated intravascular coagulation show increased plasma levels of APC-PCI complex, concomitant with a decrease in the plasma levels of PCI [4-81. PCI also inhibits thrombin [2, 91, thrombin-thrombomodulin complex [lo], factor Xa [2, 91, factor XIa, [9, 211, urokinase [12, 131, tissue plasminogen activator [12, 131, plasma kallikrein [9, 111 and several other serine proteases. Plasma PCI seems to be produced mainly in the liver [14]. The plasma level of PCI (=5 pg/ml: 4 7 . 7 nM) decreased in patients with liver diseases.On the other hand, a high concentration of PCI has been recently reported in human seminal plasma (~2 2 0 pg/ml: -3.9 pM), partly forming a complex with a serine protease, prostate-specific antigen (PSA). PCI has also been described to be present in the Graaf follicular fluid, testis, epididymis, prostate, seminal vesicle ...